MacroGenics, Inc. (MGNX) Receives $33.78 Average Target Price from Analysts
Shares of MacroGenics, Inc. (NASDAQ:MGNX) have been given an average recommendation of “Hold” by the fifteen research firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $33.78.
Several research firms have recently issued reports on MGNX. BidaskClub lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Morgan Stanley reduced their price target on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, August 7th. Cowen and Company restated a “buy” rating on shares of MacroGenics in a research report on Friday, August 4th. Zacks Investment Research lowered MacroGenics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Finally, ValuEngine lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd.
Shares of MacroGenics (MGNX) traded down 0.39% during mid-day trading on Friday, hitting $15.46. The stock had a trading volume of 47,536 shares. MacroGenics has a 12-month low of $14.36 and a 12-month high of $32.68. The stock’s market cap is $568.90 million. The firm’s 50-day moving average price is $17.10 and its 200 day moving average price is $18.64.
MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.09. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $15.82 million. During the same quarter in the prior year, the business earned $1.12 earnings per share. The firm’s revenue for the quarter was down 97.9% on a year-over-year basis. Equities analysts forecast that MacroGenics will post ($4.36) EPS for the current fiscal year.
WARNING: “MacroGenics, Inc. (MGNX) Receives $33.78 Average Target Price from Analysts” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/21/macrogenics-inc-mgnx-receives-33-78-average-target-price-from-analysts.html.
In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $20.00, for a total transaction of $100,000.00. Following the transaction, the senior vice president now directly owns 35,000 shares in the company, valued at $700,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 8.30% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC raised its position in MacroGenics by 6.0% in the second quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock valued at $91,733,000 after buying an additional 295,553 shares in the last quarter. OppenheimerFunds Inc. increased its stake in MacroGenics by 9.4% in the first quarter. OppenheimerFunds Inc. now owns 3,323,025 shares of the biopharmaceutical company’s stock valued at $61,808,000 after buying an additional 286,018 shares in the last quarter. BB Biotech AG increased its stake in MacroGenics by 4.0% in the second quarter. BB Biotech AG now owns 2,350,112 shares of the biopharmaceutical company’s stock valued at $41,150,000 after buying an additional 90,112 shares in the last quarter. Vanguard Group Inc. increased its stake in MacroGenics by 2.8% in the second quarter. Vanguard Group Inc. now owns 1,391,322 shares of the biopharmaceutical company’s stock valued at $24,362,000 after buying an additional 38,458 shares in the last quarter. Finally, Wasatch Advisors Inc. increased its stake in MacroGenics by 5,159.3% in the second quarter. Wasatch Advisors Inc. now owns 1,044,243 shares of the biopharmaceutical company’s stock valued at $18,285,000 after buying an additional 1,024,388 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.